Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study


Ozmen V., ÇAKAR B., GÖKMEN E., Ozdogan M., Guler N., Uras C. , et al.

EUROPEAN JOURNAL OF BREAST HEALTH, cilt.15, ss.183-190, 2019 (ESCI İndekslerine Giren Dergi)

  • Cilt numarası: 15 Konu: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/ejbh.2019.4761
  • Dergi Adı: EUROPEAN JOURNAL OF BREAST HEALTH
  • Sayfa Sayısı: ss.183-190

Özet

Objective: Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective.